title: Impact of oral meloxicam on circulating physiological biomarkers of stress and inflammation in beef steers after long-distance transportation.
abstract: Transportation stress can result in significant economic losses to producers due to decreased animal productivity and increased medication costs associated with sickness such as bovine respiratory disease (BRD). Meloxicam (MEL) provides pain relief and anti-inflammatory effects in cattle for several days after a single oral treatment. Our hypothesis was that MEL administration before shipping would reduce the impact of long-distance transportation on circulating physiological biomarkers of stress and inflammation in beef steers. Ninety-seven beef steers were blood sampled for baseline biomarker determination and then randomly assigned to receive either 1 mg/kg MEL (n = 49) or a placebo (CONT; n = 48) per os before a 1,316-km transportation event lasting approximately 16 h. Calves were then blood sampled on arrival and 5 d later. Changes in the hemogram, circulating plasma proteins, total carbon dioxide (TCO2), fibrinogen, substance P (SP), cortisol, haptoglobin (Hp)-matrix metalloproteinase-9 (MMP-9) complexes, and tumor necrosis factor α (TNFα) between treatments over time were compared using a mixed effects model with statistical significance designated as P < 0.05. Analysis of covariance was conducted to assess the relationship between circulating MEL concentrations and biomarker changes over time. An increase in neutrophil, platelet, monocyte, white blood cell, and red blood cell counts occurred after transportation (P < 0.0001) and a decrease in lymphocyte count were observed (P < 0.0001). Meloxicam treatment reduced the stress-induced neutrophilia (P = 0.0072) and circulating monocyte count (P = 0.013) on arrival. Mean corpuscle hemoglobin (P = 0.05), mean corpuscle volume (P = 0.05), and lymphocyte count (P = 0.05) were also greater in the CONT calves compared with MEL calves after transportation. Furthermore, Hp-MMP-9 complexes, TCO2, TNFα, plasma proteins, and SP increased and cortisol decreased after shipping (P < 0.01). Meloxicam treatment tended to reduce serum cortisol concentrations (P = 0.08) and there was evidence of a time × treatment interaction (P = 0.04). An inverse relationship between plasma MEL concentrations and circulation cortisol concentrations (P = 0.002) and neutrophil (P = 0.04) and basophil counts (P = 0.03) was also observed. The results suggest that MEL administration may reduce the impact of long-distance transportation on circulating physiological biomarkers of stress and inflammation in beef calves.
authors.affiliation: Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames 50011;
authors.forename: N K
authors.initials: NK
authors.lastname: Van Engen
authors.forename: M L
authors.initials: ML
authors.lastname: Stock
authors.forename: T
authors.initials: T
authors.lastname: Engelken
authors.forename: R C
authors.initials: RC
authors.lastname: Vann
authors.forename: L W
authors.initials: LW
authors.lastname: Wulf
authors.forename: L A
authors.initials: LA
authors.lastname: Karriker
authors.forename: W D
authors.initials: WD
authors.lastname: Busby
authors.forename: J
authors.initials: J
authors.lastname: Lakritz
authors.forename: A J
authors.initials: AJ
authors.lastname: Carpenter
authors.forename: B J
authors.initials: BJ
authors.lastname: Bradford
authors.forename: W H
authors.initials: WH
authors.lastname: Hsu
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.forename: J F
authors.initials: JF
authors.lastname: Coetzee
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000209:etiology; D007249:Inflammation / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D000077239:Meloxicam; D013312:Stress, Physiological / Q000187:drug effects* / Q000502:physiology; D013843:Thiazines / Q000008:administration & dosage / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014186:Transportation
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam